Beijing: Chinese biopharmaceutical company Sinovac Biotech is mulling to start a clinical trial of its experimental coronavirus vaccine “CoronaVac” with children and adolescents on September 28, according to reports.
The company has received approval from the Chinese regulator for the trial.
As many as 552 healthy participants aged between three and 17 will take two doses of US-listed Sinovac’s CoronaVac in a combined Phase 1 and Phase 2 trial, which is expected to begin on September 28 in the northern Chinese province of Hebei, reports added.
The Chinese firm has already administered its vaccine to about 90 per cent of the company’s employees and their families.
Earlier, Sinovac had claimed that its inactivated COVID-19 vaccine candidate showed good safety and immunogenicity on healthy adults aged 60 and above from its phase I/II clinical studies conducted in China, which is comparable to the result in healthy adults aged from 18 to 59 in the earlier studies.
Comments are closed.